Immune landscape of vulvar cancer patients treated with surgery and adjuvant radiotherapy revealed restricted T cell functionality and increased IL-17 expression associated with cancer relapse.
T cells
Th17 cells
cancer relapse
radiation
therapy
vulvar cancer
Journal
International journal of cancer
ISSN: 1097-0215
Titre abrégé: Int J Cancer
Pays: United States
ID NLM: 0042124
Informations de publication
Date de publication:
15 Jan 2024
15 Jan 2024
Historique:
revised:
31
08
2023
received:
14
06
2023
accepted:
01
09
2023
medline:
23
11
2023
pubmed:
3
10
2023
entrez:
3
10
2023
Statut:
ppublish
Résumé
For vulvar cancers, radiotherapy is targeting cancer cells, but also affects the host immune system. As this may affect treatment outcome, in this prospective study, we characterized the individual T cell immune milieu induced by surgery and adjuvant radio +/- chemotherapy (aRT) systemically in the blood of vulvar cancer patients and found increased frequencies of Interleukin (IL)-17-producing CD4
Substances chimiques
Interleukin-17
0
Perforin
126465-35-8
Programmed Cell Death 1 Receptor
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
343-358Subventions
Organisme : Else Kröner-Fresenius Stiftung
ID : 2017-A64
Organisme : Wilhelm Sander-Stiftung
ID : 2022.012.1
Informations de copyright
© 2023 The Authors. International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.
Références
Rogers LJ, Cuello MA. Cancer of the vulva. Int J Gynaecol Obstet. 2018;143(Suppl 2):4-13.
International Agency for Research on Cancer. Globocon 2018, Cancer/Vulva (C51). WHO. https://gco.iarc.fr/today/data/factsheets/cancers/21-Vulva-fact-sheet.pdf
Cohen PA, Anderson L, Eva L, Scurry J. Clinical and molecular classification of vulvar squamous pre-cancers. Int J Gynecol Cancer. 2019;29:821-828.
Nuovo GJ, Delvenne P, MacConnell P, Chalas E, Neto C, Mann WJ. Correlation of histology and detection of human papillomavirus DNA in vulvar cancers. Gynecol Oncol. 1991;43:275-280.
Carli P, Cattaneo A, De Magnis A, Biggeri A, Taddei G, Giannotti B. Squamous cell carcinoma arising in vulval lichen sclerosus: a longitudinal cohort study. Eur J Cancer Prev. 1995;4:491-495.
Buttmann-Schweiger N, Klug SJ, Luyten A, et al. Incidence patterns and temporal trends of invasive nonmelanotic vulvar tumors in Germany 1999-2011. A population-based cancer registry analysis. PLoS One. 2015;10:e0128073.
Borella F, Preti M, Bertero L, et al. Is there a place for immune checkpoint inhibitors in vulvar neoplasms? A state of the art review. Int J Mol Sci. 2021;22:190.
Chan JK, Sugiyama V, Pham H, et al. Margin distance and other clinico-pathologic prognostic factors in vulvar carcinoma: a multivariate analysis. Gynecol Oncol. 2007;104:636-641.
Mert I, Cliby WA, Bews KA, Habermann EB, Dowdy SC. Evidence-based wound classification for vulvar surgery: implications for risk adjustment. Gynecol Oncol. 2019;154:280-282.
te Grootenhuis NC, Pouwer AW, de Bock GH, et al. Prognostic factors for local recurrence of squamous cell carcinoma of the vulva: a systematic review. Gynecol Oncol. 2018;148:622-631.
Homesley HD, Bundy BN, Sedlis A, et al. Assessment of current International Federation of Gynecology and Obstetrics staging of vulvar carcinoma relative to prognostic factors for survival (a Gynecologic Oncology Group study). Am J Obstet Gynecol. 1991;164:997-1003. discussion 1004.
Kortekaas KE, Santegoets SJ, Tas L, et al. Primary vulvar squamous cell carcinomas with high T cell infiltration and active immune signaling are potential candidates for neoadjuvant PD-1/PD-L1 immunotherapy. J Immunother Cancer. 2021;9:e003671.
Wanka G, Schmoeckel E, Mayr D, et al. LDOC1 as negative prognostic marker for vulvar cancer patients. Int J Mol Sci. 2020;21:9287.
Ansorge N, Dannecker C, Jeschke U, et al. Combined COX-2/PPARgamma expression as independent negative prognosticator for vulvar cancer patients. Diagnostics (Basel). 2021;11:491.
Heeren AM, Rotman J, Samuels S, et al. Immune landscape in vulvar cancer-draining lymph nodes indicates distinct immune escape mechanisms in support of metastatic spread and growth. J Immunother Cancer. 2021;9:e003623.
Woelber L, Prieske K, Eulenburg CZ, et al. Adjuvant radiotherapy and local recurrence in vulvar cancer: a subset analysis of the AGO-CaRE-1 study. Gynecol Oncol. 2022;164:68-75.
van Meir H, Nout RA, Welters MJ, et al. Impact of (chemo)radiotherapy on immune cell composition and function in cervical cancer patients. Onco Targets Ther. 2017;6:e1267095.
Zheng X, Guo Y, Wang L, et al. Recovery profiles of T-cell subsets following low-dose total body irradiation and improvement with cinnamon. Int J Radiat Oncol Biol Phys. 2015;93:1118-1126.
Kryczek I, Zhao E, Liu Y, et al. Human TH17 cells are long-lived effector memory cells. Sci Transl Med. 2011;3:104ra0.
Schuler PJ, Harasymczuk M, Schilling B, et al. Effects of adjuvant chemoradiotherapy on the frequency and function of regulatory T cells in patients with head and neck cancer. Clin Cancer Res. 2013;19:6585-6596.
Theobald L, Stroeder R, Melchior P, et al. Chemoradiotherapy-induced increase in Th17 cell frequency in cervical cancer patients is associated with therapy resistance and early relapse. Mol Oncol. 2021;15:3559-3577.
Patil RS, Shah SU, Shrikhande SV, Goel M, Dikshit RP, Chiplunkar SV. IL17 producing gammadeltaT cells induce angiogenesis and are associated with poor survival in gallbladder cancer patients. Int J Cancer. 2016;139:869-881.
Luckel C, Picard FSR, Huber M. Tc17 biology and function: novel concepts. Eur J Immunol. 2020;50:1257-1267.
Zhang ZS, Gu Y, Liu BG, Tang H, Hua Y, Wang J. Oncogenic role of Tc17 cells in cervical cancer development. World J Clin Cases. 2020;8:11-19.
Kortekaas KE, Santegoets SJ, Sturm G, et al. CD39 identifies the CD4(+) tumor-specific T-cell population in human cancer. Cancer Immunol Res. 2020;8:1311-1321.
Timperi E, Barnaba V. CD39 regulation and functions in T cells. Int J Mol Sci. 2021;22:8068.
Allard D, Allard B, Stagg J. On the mechanism of anti-CD39 immune checkpoint therapy. J Immunother Cancer. 2020;8:e000186.
Guo S, Han F, Zhu W. CD39: a bright target for cancer immunotherapy. Biomed Pharmacother. 2022;151:113066.
Sharpe AH, Pauken KE. The diverse functions of the PD1 inhibitory pathway. Nat Rev Immunol. 2018;18:153-167.
Witteveen PO, van der Velden J, Vergote I, et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer-Gynaecological Cancer Group). Ann Oncol. 2009;20:1511-1516.
Cormio G, Loizzi V, Gissi F, et al. Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. Oncology. 2009;77:281-284.
Preti M, Bucchi L, Micheletti L, et al. Four-decade trends in lymph node status of patients with vulvar squamous cell carcinoma in northern Italy. Sci Rep. 2021;11:5661.
Mahner S, Jueckstock J, Hilpert F, et al. Adjuvant therapy in lymph node-positive vulvar cancer: the AGO-CaRE-1 study. J Natl Cancer Inst. 2015;107:dju426.
Fang Y, Yu S, Ellis JS, Sharav T, Braley-Mullen H. Comparison of sensitivity of Th1, Th2, and Th17 cells to Fas-mediated apoptosis. J Leukoc Biol. 2010;87:1019-1028.
Nguyen HQ, Belkacemi Y, Mann C, et al. Human CCR6+ Th17 lymphocytes are highly sensitive to radiation-induced senescence and are a potential target for prevention of radiation-induced toxicity. Int J Radiat Oncol Biol Phys. 2019;108:314-325.
Wang L, Zhang Y, Xie F. T-regulatory cell/T helper 17 cell imbalance functions as prognostic biomarker of oral squamous cell carcinoma: CONSORT. Medicine (Baltimore). 2020;99:e23145.
Lin W, Zhang HL, Niu ZY, et al. The disease stage-associated imbalance of Th1/Th2 and Th17/Treg in uterine cervical cancer patients and their recovery with the reduction of tumor burden. BMC Womens Health. 2020;20:126.
Asadzadeh Z, Mohammadi H, Safarzadeh E, et al. The paradox of Th17 cell functions in tumor immunity. Cell Immunol. 2017;322:15-25.
Amicarella F, Muraro MG, Hirt C, et al. Dual role of tumour-infiltrating T helper 17 cells in human colorectal cancer. Gut. 2017;66:692-704.
Wang L, Yi T, Kortylewski M, Pardoll DM, Zeng D, Yu H. IL-17 can promote tumor growth through an IL-6-Stat3 signaling pathway. J Exp Med. 2009;206:1457-1464.
Feng M, Wang Y, Chen K, Bian Z, Jinfang W, Gao Q. IL-17A promotes the migration and invasiveness of cervical cancer cells by coordinately activating MMPs expression via the p38/NF-kappaB signal pathway. PLoS One. 2014;9:e108502.
Gupta PK, Godec J, Wolski D, et al. CD39 expression identifies terminally exhausted CD8+ T cells. PLoS Pathog. 2015;11:e1005177.
Longhi MS, Moss A, Bai A, et al. Characterization of human CD39+ Th17 cells with suppressor activity and modulation in inflammatory bowel disease. PLoS One. 2014;9:e87956.
Bai A, Moss A, Kokkotou E, et al. CD39 and CD161 modulate Th17 responses in Crohn's disease. J Immunol. 2014;193:3366-3377.
Tailor A, Estephan H, Parker R, et al. Ionizing radiation drives key regulators of antigen presentation and a global expansion of the immunopeptidome. Mol Cell Proteomics. 2022;21:100410.
Bogani G, Palaia I, Perniola G, et al. An update on current pharmacotherapy for vulvar cancer. Expert Opin Pharmacother. 2023;24:95-103.
Praiss A, Navitski A, Cohen S, Tessier-Cloutier B, Broach V, O'Cearbhaill RE. Immunotherapy for recurrent or metastatic vulvar carcinoma: a case report and review of current guidelines. Gynecol Oncol Rep. 2022;41:100982.
How JA, Jazaeri AA, Soliman PT, et al. Pembrolizumab in vaginal and vulvar squamous cell carcinoma: a case series from a phase II basket trial. Sci Rep. 2021;11:3667.
Hecking T, Thiesler T, Schiller C, et al. Tumoral PD-L1 expression defines a subgroup of poor-prognosis vulvar carcinomas with non-viral etiology. Oncotarget. 2017;8:92890-92903.
Xiang T, Long H, He L, et al. Interleukin-17 produced by tumor microenvironment promotes self-renewal of CD133+ cancer stem-like cells in ovarian cancer. Oncogene. 2015;34:165-176.
Gran F, Kerstan A, Serfling E, Goebeler M, Muhammad K. Current developments in the immunology of psoriasis. Yale J Biol Med. 2020;93:97-110.
Verstockt B, Deleenheer B, van Assche G, Vermeire S, Ferrante M. A safety assessment of biological therapies targeting the IL-23/IL-17 axis in inflammatory bowel diseases. Expert Opin Drug Saf. 2017;16:809-821.
Fabre J, Giustiniani J, Garbar C, et al. Targeting the tumor microenvironment: the protumor effects of IL-17 related to cancer type. Int J Mol Sci. 2016;17:1433.
Ibrahim S, Girault A, Ohresser M, et al. Monoclonal antibodies targeting the IL-17/IL-17RA axis: An opportunity to improve the efficiency of anti-VEGF therapy in fighting metastatic colorectal cancer? Clin Colorectal Cancer. 2018;17:e109-e113.